We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Even as Cyberonics plans the market rollout of its vagus nerve stimulator (VNS) system to treat depression in adults, critics are charging that the FDA rushed to judgment over a product that has not yet been proven to work effectively — or even at all.